Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.

Abstract: The system obtains multiple unique identifiers associated with multiple UEs, where a unique identifier among the multiple unique identifiers identifies a UE among the multiple UEs. Based on the unique identifier, the system determines multiple technical capabilities associated with the multiple UEs. The system receives a request for one or more UEs, where the request includes a number of the one or more UEs and a desired technical capability associated with the one or more UEs, and where the request is specified at a level of abstraction that allows more than one UE among the multiple UEs to satisfy the request. Based on the request for the one or more UEs and the multiple technical capabilities associated with the multiple UEs, the system determines a subset of the multiple UEs satisfying the request, and sends a response to the request indicating the subset of the multiple UEs satisfying the request.